3.93
+1.66(+73.13%)
Currency In USD
| Previous Close | 2.27 |
| Open | 5.57 |
| Day High | 6.2 |
| Day Low | 3.49 |
| 52-Week High | 6.2 |
| 52-Week Low | 1.33 |
| Volume | 90.1M |
| Average Volume | 27,921 |
| Market Cap | 28.36M |
| PE | -3.2 |
| EPS | -1.23 |
| Moving Average 50 Days | 2.1 |
| Moving Average 200 Days | 2.61 |
| Change | 1.66 |
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms
GlobeNewswire Inc.
8 hours ago
• Significantly expands IB-Stim’s total addressable market • Clearance covers patients aged 8–21 • Seamless go-to-market strategy with existing reimbursement and provider infrastructure CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis,
NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025
GlobeNewswire Inc.
May 05, 2025 1:00 PM GMT
Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern TimeCARMEL, Ind., May 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology c
NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025
GlobeNewswire Inc.
Apr 15, 2025 1:00 PM GMT
CARMEL, Ind., April 15, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children